Anticipated Spike in Deal Activity in 2021 Makes Customized R&W Insurance Critical, Finds Lowenstein Sandler

NEW YORK–(BUSINESS WIRE)–Encouraging news about COVID-19 vaccination trials and the impending resolution of the long election process bode well for deal activity in 2021, according to M&A and insurance recovery lawyers from Lowenstein Sandler. With an anticipated increase in financial transactions, competition among insurers is also expected to heat up, making this an ideal time … [Read more…]

ImmunityBio Simulates SARS-CoV-2 Spike Protein Binding Using Molecular Dynamics

Detailed computer modeling, completed in partnership with Microsoft, explains virulence of COVID-19 and provides key information that may lead to a better understanding of the multiple mutations currently occurring to the “spike” protein as the virus evolves Computer-based molecular dynamics simulation allows highly detailed visualization of free (unbound) spike receptor binding domain (S RBD) and … [Read more…]

Vicks® Donates $1 million for COVID-19 Health Care Relief

Humanitarian Aid Organization, Direct Relief, will use the funds to deliver protective gear and essential medical aid to health care organizations CINCINNATI–(BUSINESS WIRE)–In response to the novel coronavirus (COVID-19) pandemic, the Vicks® family of cold and flu brands – NyQuil™, DayQuil™ and VapoRub™ – will donate $1 million to Direct Relief, one of the world’s … [Read more…]

Oragenics Issues Letter to Stockholders

Provides update on competitive positioning of Terra CoV-2 vaccine against SARS-CoV-2, expects to file IND in 3Q21 TAMPA, Fla.–(BUSINESS WIRE)–Oragenics, Inc. (NYSE American: OGEN) today issued the following letter to stockholders from its President and Chief Executive Officer, Alan Joslyn, Ph.D.: To My Fellow Stockholders, With so much encouraging news recently around COVID-19 vaccine development, … [Read more…]

Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59

CT-P59 (40mg/kg) treated patients reported reduced progression rates to severe COVID-19 by 54% for patients with mild-to-moderate symptoms and 68% for moderate patients aged 50 years and over CT-P59 (40mg/kg) treated patients reported a significantly shortened time to clinical recovery ranging from 3.4 to 6.4 days quicker compared to placebo A significant reduction of viral … [Read more…]

Oragenics Announces Closing of $6.5 Million Registered Direct Offering

TAMPA, Fla.–(BUSINESS WIRE)–Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, today announced the closing of its previously announced registered direct offering of 14,444,444 shares of common stock at a purchase price of $0.45 per share. A.G.P./Alliance … [Read more…]

Shift4 Payments: As Merchants Persevere Throughout the Fall, Transaction Volumes Show Continuing Impact of COVID-19

Despite an October in which transaction volumes exceeded seasonal expectations, November transaction volumes reveal the impact of the ongoing pandemic ALLENTOWN, Pa. & LAS VEGAS–(BUSINESS WIRE)–Shift4 Payments (NYSE: FOUR), the leader in integrated payment processing solutions, has revealed that the month-over-month change in U.S. merchant transaction volumes from October to November dipped more than in … [Read more…]

ImmunityBio’s hAd5 T-Cell COVID-19 Vaccine Candidate Shows Complete Protection of Airways in Non-Human Primates

BARDA-sponsored study shows second-generation hAd5 vaccine candidate in both subcutaneous and room temperature oral formulations inhibits SARS-CoV-2 virus replication to undetectable levels and clears infection within days in 100% of vaccinated non-human primates The second-generation human adenovirus vector hAd5, which delivers both outer spike (S) and inner nucleocapsid (N) antigens, induced T cells and antibodies … [Read more…]

Moderna Provides Updates on the Clinical Development and Production of Its COVID-19 Vaccine Candidate

Interim durability data from NIH-led Phase 1 study of mRNA-1273 published as letter to the editor in NEJM; at day 119, 3 months post-second 100 μg dose, binding and neutralizing antibody titers remain high in all participants; results consistent across all age groups (18-55, 56-70 and 71+) Company reaffirms expectation to have 20 million doses … [Read more…]

Moderna Announces Amendment to Current Supply Agreement with United Kingdom Government for an Additional 2 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

UK government has now secured 7 million doses of mRNA-1273 Agreement reflects Moderna’s commitment to make its vaccine available in multiple countries CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a supply agreement with the … [Read more…]